Immunogenicity and safety of GSK Biologicals' candidate tuberculosis (TB) vaccine (692342) when administered to healthy adults aged 21 to 40 years.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 692342 (Primary)
Indications Tuberculosis
Focus Adverse reactions; Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

15 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
15 Jul 2008 The expected completion date for this trial has been extended from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.
15 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight